Skip to main content

Rheumatoid Arthritis

      JAK1 TYK2 in RA
      Steroids and MACE in RA
      Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel interv

      Dr. Antoni Chan

      1 year 10 months ago
      Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel intervention is required in RA, Baker MC, #ACR23 @RheumNow https://t.co/agLtRKdDTf
      🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases ?

      Mithu Maheswaranathan, MD

      1 year 10 months ago
      🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases 🫁 🔸 Screening & Monitoring Recs 🔸 Treatment Guidelines ILD/RP-ILD #RheumTwitter #PulmTwitter #MedTwitter #MedX https://t.co/JreVO0kgEf
      Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

      Mithu Maheswaranathan, MD

      1 year 10 months ago
      Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

      Dr. John Cush RheumNow

      1 year 10 months ago
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv
      Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after imm

      Jeffrey Sparks MD MMSc jeffsparks

      1 year 10 months ago
      Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor. 46% flared Seropositive- OR 2.0 NO association with mortality -ICIs are safe to use in RA -Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
      LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were gener

      Dr. Antoni Chan

      1 year 10 months ago
      LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I
      #ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study.

      Dr. Rachel Tate

      1 year 10 months ago
      #ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study. https://t.co/d0ZBWDKZlB https://t.co/EdllyGUT1y
      Rx of #inflammatory #arthritis with #glucocorticoids doesn’t seem to affect outcomes in #malignancy treated with #chec

      Janet Pope

      1 year 10 months ago
      Rx of #inflammatory #arthritis with #glucocorticoids doesn’t seem to affect outcomes in #malignancy treated with #checkpoint #inhibitors. Good news as new or flaring inflammatory arthritis as an irAE can be severe. #ACR23 @RheumNow @ACRheum #1055 @CanRIO_Tweets https://t.co/tFIPcQq2X6
      Tapering ABA vs. stable dose ABA in RA

      No diff in DAS28 remission at 2 years

      But…

      Only in patients receiving conco

      Aurelie Najm

      1 year 10 months ago
      Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
      The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis.

      Intervention inc

      sheila

      1 year 10 months ago
      The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis. Intervention included food delivery svc & probiotic shot Limitations included study design issues such small sample size #ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
      ×